Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk; Maarten Slagter; Hugo M Horlings; Karolina Sikorska; Koen K van de Vijver; Michiel de Maaker; Iris Nederlof; Roelof J C Kluin; Sarah Warren; SuFey Ong; Terry G Wiersma; Nicola S Russell; Ferry Lalezari; Philip C Schouten; Noor A M Bakker; Steven L C Ketelaars; Dennis Peters; Charlotte A H Lange; Erik van Werkhoven; Harm van Tinteren; Ingrid A M Mandjes; Inge Kemper; Suzanne Onderwater; Myriam Chalabi; Sofie Wilgenhof; John B A G Haanen; Roberto Salgado; Karin E de Visser; Gabe S Sonke; Lodewyk F A Wessels; Sabine C Linn; Ton N Schumacher; Christian U Blank; Marleen Kok

doi:10.1038/s41591-019-0520-5

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

Authors

Leonie Voorwerk^#¹, Maarten Slagter^#^{1

2

3}, Hugo M Horlings⁴, Karolina Sikorska⁵, Koen K van de Vijver^{4

6}, Michiel de Maaker⁷, Iris Nederlof⁷, Roelof J C Kluin⁸, Sarah Warren⁹, SuFey Ong⁹, Terry G Wiersma¹⁰, Nicola S Russell¹⁰, Ferry Lalezari¹¹, Philip C Schouten⁷, Noor A M Bakker^{3

12}, Steven L C Ketelaars¹, Dennis Peters¹³, Charlotte A H Lange¹¹, Erik van Werkhoven⁵, Harm van Tinteren⁵, Ingrid A M Mandjes⁵, Inge Kemper¹⁴, Suzanne Onderwater¹⁴, Myriam Chalabi^{1

15}, Sofie Wilgenhof¹⁴, John B A G Haanen^{1

14}, Roberto Salgado^{16

17}, Karin E de Visser^{3

12}, Gabe S Sonke¹⁴, Lodewyk F A Wessels^{2

3}, Sabine C Linn^{7

14}, Ton N Schumacher^{1

3}, Christian U Blank^{1

14}, Marleen Kok^{18

19}

Affiliations

¹ Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
² Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
³ Oncode Institute, Utrecht, the Netherlands.
⁴ Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁵ Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁶ Department of Pathology, Ghent University Hospital, Ghent, Belgium.
⁷ Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁸ Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁹ NanoString Technologies, Inc, Seattle, WA, USA.
¹⁰ Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹¹ Department of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹² Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹³ Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹⁴ Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹⁵ Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
¹⁶ Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.
¹⁷ Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia.
¹⁸ Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [email protected].
¹⁹ Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. [email protected].

^# Contributed equally.

PMID: 31209337
DOI: 10.1038/s41591-019-0520-5

Abstract

In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read "TGF-α signaling via NF-κB". It should have read "TNF-α signaling via NF-κB". The error has been corrected in the HTML and PDF versions of this article.

Publication types

Published Erratum